Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy
Linrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan · 2026
Read Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy by Linrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13502141.txt.
Description
Linrong Li leads a five-author team with a 2026 review of antibody-encapsulated drugs, a proposed successor to antibody-drug conjugates in cancer therapy. Conjugates weld a poison to an antibody, but the welding is uneven: drug-to-antibody ratios vary, linkers can leak early, and production is complex. The new platform instead tucks a fixed number of drug molecules inside an antibody without a covalent bond, using a technique called single protein encapsulation. That promises exact dosing, less premature release, and simpler production.
The proof-of-concept pairs trastuzumab, a HER2-targeting antibody, with actinomycin D sealed inside it. Across cancer models with varying HER2 levels the construct killed tumours while showing a friendly toxicity profile in animals. Parallel trials of albumin-encapsulated medicines support the wider platform. The authors position the approach as a way past conjugate resistance and limits, widening which payloads and proteins can be used.
Catalog record
| CREATOR | Linrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11858 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |